CIAM
NSRX

Caitong International Asset Management’s Nasus Pharma NSRX Stock Holding History

Caitong International Asset Management’s Portfolio NSRX Stock Details NSRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14 Buy
+4
New +$12 ﹤0.01% 2589

Other funds holding NSRX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Caitong International Asset Management's NSRX Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Nasus Pharma (NSRX) in Q2 2026: 4 shares worth $14. The stake represents ﹤0.01% of the portfolio and ranks #2589 among its holdings.

10 funds tracked by Wall St. Rank hold NSRX as of Q2 2026.

  • Caitong International Asset Management held 4 shares of Nasus Pharma worth $14 as of Q2 2026.
  • Nasus Pharma was a new Caitong International Asset Management position in Q2 2026.
  • Nasus Pharma made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2589 holding.
  • 10 funds tracked by Wall St. Rank held Nasus Pharma as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.